Last reviewed · How we verify
AZD2936
AZD2936 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
AZD2936 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | AZD2936 |
|---|---|
| Also known as | rilvegostomig, Rilvegostomig |
| Sponsor | AstraZeneca |
| Drug class | PI3K delta and PI3K gamma inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, AZD2936 reduces the activity of the PI3K/AKT signaling pathway, which is involved in the regulation of immune cell function. This leads to a decrease in the proliferation and survival of immune cells, resulting in anti-inflammatory effects.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Musculoskeletal pain
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Pyrexia
- Cough
Key clinical trials
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (PHASE3)
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (PHASE1, PHASE2)
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies (PHASE1, PHASE2)
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (PHASE2)
- A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (PHASE1)
- A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (PHASE3)
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (PHASE3)
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2936 CI brief — competitive landscape report
- AZD2936 updates RSS · CI watch RSS
- AstraZeneca portfolio CI